Journal article
A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
The Journal of infectious diseases, Vol.203(10), pp.1396-1404
05/15/2011
DOI: 10.1093/infdis/jir054
PMCID: PMC3080891
PMID: 21398392
Abstract
Methods. A DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV under the transcriptional control of the CMV/R promoter was evaluated in an open-label study in 30 healthy adults. Half of the subjects were age 18-50 years and half were age 51-65 years. Immune responses were assessed by enzyme-linked immunosorbent assay, neutralization assays, intracellular cytokine staining, and ELISpot.
Results. The 3-dose vaccine regimen was safe and well tolerated. Vaccine-induced T cell and neutralizing antibody responses were detected in the majority of subjects. The antibody responses seen in the older age group were of similar frequency, magnitude, and duration as those seen in the younger cohort.
Conclusions. Neutralizing antibody responses to WNV were elicited by DNA vaccination in humans, including in older individuals, where responses to traditional vaccine approaches are often diminished. This DNA vaccine elicited T cell responses of greater magnitude when compared with an earlier-generation construct utilizing a CMV promoter.
Clinical Trials Registration. NCT00300417.
Details
- Title: Subtitle
- A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
- Creators
- Julie E. Ledgerwood - NIAID, VRC, NIH, Bethesda, MD 20892 USATheodore C. Pierson - Global ViralSarah A. Hubka - NIAID, VRC, NIH, Bethesda, MD 20892 USANiraj Desai - NIAID, VRC, NIH, Bethesda, MD 20892 USASteve Rucker - NIAID, VRC, NIH, Bethesda, MD 20892 USAIngelise J. Gordon - NIAID, VRC, NIH, Bethesda, MD 20892 USAMary E. Enama - NIAID, VRC, NIH, Bethesda, MD 20892 USASteevenson Nelson - Global ViralMartha Nason - National Institute of Allergy and Infectious DiseasesWenjuan Gu - Science Applications International CorporationNikkida Bundrant - NIAID, VRC, NIH, Bethesda, MD 20892 USARichard A. Koup - NIAID, VRC, NIH, Bethesda, MD 20892 USARobert T. Bailer - NIAID, VRC, NIH, Bethesda, MD 20892 USAJohn R. Mascola - NIAID, VRC, NIH, Bethesda, MD 20892 USAGary J. Nabel - NIAID, VRC, NIH, Bethesda, MD 20892 USABarney S. Graham - NIAID, VRC, NIH, Bethesda, MD 20892 USAVRC 303 Study Team
- Resource Type
- Journal article
- Publication Details
- The Journal of infectious diseases, Vol.203(10), pp.1396-1404
- DOI
- 10.1093/infdis/jir054
- PMID
- 21398392
- PMCID
- PMC3080891
- NLM abbreviation
- J Infect Dis
- ISSN
- 1537-6613
- eISSN
- 0022-1899
- Publisher
- Oxford Univ Press
- Number of pages
- 9
- Grant note
- National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) ZIAAI001022 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)
- Language
- English
- Date published
- 05/15/2011
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984949466102771
Metrics
2 Record Views